SMT201600430B - Inibitori di chinasi e loro uso nel trattamento del cancro - Google Patents

Inibitori di chinasi e loro uso nel trattamento del cancro

Info

Publication number
SMT201600430B
SMT201600430B SM201600430T SM201600430T SMT201600430B SM T201600430 B SMT201600430 B SM T201600430B SM 201600430 T SM201600430 T SM 201600430T SM 201600430 T SM201600430 T SM 201600430T SM T201600430 B SMT201600430 B SM T201600430B
Authority
SM
San Marino
Prior art keywords
chinase
inhibitors
cancer treatment
cancer
treatment
Prior art date
Application number
SM201600430T
Other languages
English (en)
Inventor
Peter Brent Sampson
Yong Liu
Sze-Wan Li
Bryan T Forrest
Heinz W Pauls
Louise G Edwards
Miklos Feher
Narendra Kumar B Patel
Radoslaw Laufer
Guohua Pan
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SMT201600430B publication Critical patent/SMT201600430B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201600430T 2010-04-06 2016-11-24 Inibitori di chinasi e loro uso nel trattamento del cancro SMT201600430B (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32133210P 2010-04-06 2010-04-06
US32132910P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (1)

Publication Number Publication Date
SMT201600430B true SMT201600430B (it) 2017-01-10

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600430T SMT201600430B (it) 2010-04-06 2016-11-24 Inibitori di chinasi e loro uso nel trattamento del cancro

Country Status (25)

Country Link
US (9) US8921545B2 (it)
EP (2) EP2556070B1 (it)
JP (1) JP5442906B2 (it)
KR (1) KR101782668B1 (it)
CN (1) CN102892766B (it)
AU (1) AU2011238384B2 (it)
BR (1) BR112012025496B1 (it)
CY (1) CY1118610T1 (it)
DK (1) DK2556071T3 (it)
EA (1) EA023173B1 (it)
ES (2) ES2603613T3 (it)
HR (1) HRP20161498T1 (it)
HU (1) HUE030651T2 (it)
IL (1) IL221556A (it)
LT (1) LT2556071T (it)
ME (1) ME02545B (it)
MX (1) MX2012011516A (it)
NZ (1) NZ602350A (it)
PL (1) PL2556071T3 (it)
PT (1) PT2556071T (it)
SG (1) SG183875A1 (it)
SI (1) SI2556071T1 (it)
SM (1) SMT201600430B (it)
TW (1) TWI516262B (it)
WO (2) WO2011123947A1 (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709536C (en) 2007-12-21 2016-05-31 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
PL2556071T3 (pl) * 2010-04-06 2017-02-28 University Health Network Inhibitory kinaz i ich zastosowanie w leczeniu raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9512119B2 (en) * 2012-07-27 2016-12-06 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
CN105764899B (zh) * 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
AU2014336917B2 (en) * 2013-10-18 2018-11-29 University Health Network Treatment for pancreatic cancer
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
JP7164203B2 (ja) 2017-02-08 2022-11-01 中国医▲薬▼研究▲開▼▲発▼中心有限公司 ピロロ芳香族複素環化合物及びその製造方法並びに医薬用途
CN108947970B (zh) * 2017-05-18 2022-04-05 四川大学 吲唑类衍生物及其制备方法和用途
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
KR20220004102A (ko) * 2019-04-24 2022-01-11 유니버시티 헬스 네트워크 Plk4 억제제 (1r,2s)-(e)-2-(3-(4-((시스-2,6-디메틸모르폴리노)메틸)스티릴)-1h-이미다졸-6-일)-5'-메톡시스피로[시클로프로판-1,3'-인돌린]-2'-온 푸마레이트의 결정 형태 s4
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
KR20240035390A (ko) 2021-05-11 2024-03-15 오릭 파마슈티칼스, 인크. 폴로 유사 키나제 4 억제제
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2024006379A1 (en) * 2022-06-30 2024-01-04 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1247803A3 (en) 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2003101968A1 (fr) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Compose de pyrazole et composition medicinale le contenant
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8207179B2 (en) 2007-06-12 2012-06-26 Boehringer Ingelheim International Gmbh Substituted indolines as tyrosine kinase inhibitors
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
CA2706075A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
CA2709536C (en) * 2007-12-21 2016-05-31 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
WO2009111868A1 (en) * 2008-03-11 2009-09-17 University Health Network Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
US20100016421A1 (en) 2008-06-16 2010-01-21 Burger Angelika M Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
PL2556071T3 (pl) 2010-04-06 2017-02-28 University Health Network Inhibitory kinaz i ich zastosowanie w leczeniu raka
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
CN105764899B (zh) 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
AU2014336917B2 (en) 2013-10-18 2018-11-29 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
BR112012025496B1 (pt) 2021-02-23
TW201134471A (en) 2011-10-16
KR101782668B1 (ko) 2017-09-27
WO2011123946A8 (en) 2011-12-08
US20110263598A1 (en) 2011-10-27
WO2011123947A8 (en) 2011-12-22
BR112012025496A2 (pt) 2020-08-18
US9907800B2 (en) 2018-03-06
CN102892766B (zh) 2015-05-20
US20170226088A1 (en) 2017-08-10
HRP20161498T1 (hr) 2016-12-16
CY1118610T1 (el) 2017-07-12
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
IL221556A (en) 2015-04-30
US20120264800A1 (en) 2012-10-18
US9139563B2 (en) 2015-09-22
US9579327B2 (en) 2017-02-28
SG183875A1 (en) 2012-10-30
ES2639757T3 (es) 2017-10-30
ES2603613T3 (es) 2017-02-28
KR20130108065A (ko) 2013-10-02
US20130096301A1 (en) 2013-04-18
US20140045838A1 (en) 2014-02-13
PL2556071T3 (pl) 2017-02-28
EP2556071A1 (en) 2013-02-13
WO2011123946A1 (en) 2011-10-13
US8921545B2 (en) 2014-12-30
EP2556071B1 (en) 2016-08-17
US8263596B2 (en) 2012-09-11
EP2556070B1 (en) 2017-06-07
NZ602350A (en) 2014-05-30
AU2011238384A1 (en) 2012-09-27
AU2011238384B2 (en) 2015-02-19
US9796703B2 (en) 2017-10-24
MX2012011516A (es) 2013-03-08
US10358436B2 (en) 2019-07-23
PT2556071T (pt) 2016-11-22
US20150133677A1 (en) 2015-05-14
EP2556071A4 (en) 2013-09-04
CN102892766A (zh) 2013-01-23
EP2556070A4 (en) 2013-10-23
EA023173B1 (ru) 2016-04-29
TWI516262B (zh) 2016-01-11
DK2556071T3 (en) 2016-12-12
US20160045511A1 (en) 2016-02-18
US8481533B2 (en) 2013-07-09
ME02545B (me) 2017-02-20
JP5442906B2 (ja) 2014-03-19
LT2556071T (lt) 2017-01-25
US10077255B2 (en) 2018-09-18
EP2556070A1 (en) 2013-02-13
EA201270752A1 (ru) 2013-04-30
HUE030651T2 (en) 2017-05-29
JP2013523784A (ja) 2013-06-17
US20180105511A1 (en) 2018-04-19
SI2556071T1 (sl) 2016-12-30

Similar Documents

Publication Publication Date Title
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
SMT201400146B (it) Morfolino pirimidine e loro uso in terapia
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IT1400425B1 (it) Modified snrnas for use in therapy.
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
GB201004137D0 (en) Phytocannabinoids in the treatment of cancer
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
BR112013011659A2 (pt) métodos de tratamento do câncer
DK2883954T3 (da) Peptidbibliotek og anvendelse deraf
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
HK1215672A1 (zh) 用於治療炎症和癌症的吲哚類化合物
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
EP2773340A4 (en) USE OF SIALIDASE INHIBITORS (NEU1) IN THE TREATMENT OF CANCER
EP3069117A4 (en) Standing wave reduction in direct field acoustic testing
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
BR112014001430A2 (pt) letalidade sintética e o tratamento do câncer
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
EP3042955A4 (en) Use of rhoa in cancer diagnosis and inhibitor screening
SMT201600363B (it) Modafinil per l’uso nel trattamento di ***omani
TH1201006302B (th) ฟอสฟาพลาตินและการใช้เพื่อรักษาโรคมะเร็ง (Phosphaplatins and their use for treatment of cancers)
RS55471B1 (sr) Inhibitori kinaze i njihova upotreba za lečenje kancera